Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]

Next Previous
X
Search
Trial Profile

The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary) ; Antithymocyte globulin; Methylprednisolone; Obinutuzumab; Rituximab
  • Indications Heart transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms DUET
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 12 May 2023 Primary endpoint has not been met (Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction), as per Results published in the Journal of Heart and Lung Transplantation
    • 12 May 2023 Results published in the Journal of Heart and Lung Transplantation
    • 17 Aug 2021 Results (n=18) comapring clinical characteristics and outcomes of patients who received eculizumab for the treatment of AMR with control group, published in the Clinical Transplantation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top